One promising approach for the gene therapy of Duchenne muscular dystrophy (DMD) is exon skipping. When thinking of possible intervention on human, it is very crucial to identify the most appropriate antisense sequences able to provide the highest possible skipping efficiency. In this article, we compared the exon 51 skipping activity of 10 different antisense molecules, raised against splice junctions and/or exonic splicing enhancers (ESEs), expressed as part of the U1 small nuclear RNA (snRNA). The effectiveness of each construct was tested in human DMD myoblasts carrying the deletion of exons 48-50, which can be treated with skipping of exon 51. Our results show that the highest skipping activity and dystrophin rescue is achieved upon expression of a U1 snRNA-derived antisense molecule targeting exon 51 splice sites in combination with an internal exon sequence. The efficacy of this molecule was further proven on an exon 45-50 deletion background, utilizing patient's fibroblasts transdifferentiated into myoblasts. In this system, we showed that the selected antisense was able to produce 50% skipping of exon 51.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is one of the most severe neuromuscular diseases, a ecting 1:3,500 live males. DMD is a monogenic disorder caused by mutations in the largest gene of higher eukaryotes, the gene encoding for the dystrophin protein (DMD).
1,2 About 98% of the 2.4-Mb DMD gene accounts for intron sequences, whereas the remainder constitutes of 79 exons and seven di erent promoters, which direct the expression of tissue-speci c isoforms. Additional isoforms also arise from alternative splicing or polyadenylation. 3 In skeletal muscle tissues, dystrophin is localized on the inner face of sarcolemma, the muscle ber plasma membrane, where it interacts with the cytoskeletal actin by its N-terminal domain, and with a complex of proteins localized on the sarcolemma, named dystrophin-associated protein complex, through its C-terminal.
ese interactions allow muscle force transduction and are essential for ber integrity. 4 Several other crucial aspects of the muscle ber physiology, like calcium homeostasis, 5 and epigenetic control of gene expression, have recently emerged as dystrophindependent (ref. 6 ; Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, Morlando M et al., in preparation), providing an explanation for the dramatic consequence observed on the muscle tissue of Duchenne patients where dystrophin is absent.
Due to the well-de ned genetic alteration, many studies have concentrated on nding possible therapeutic approaches for the treatment of DMD. [7] [8] [9] With a few exceptions, all DMD mutations (deletions and duplications) lead to frameshi s, resulting in the formation of a premature termination codon that impairs dystrophin translation. 10 On the contrary, when mutations do not perturb the correct reading frame, as in the case of Becker muscular dystrophy, the translation of a partially functional protein is still occurring. Notably, Becker muscular dystrophy patients carrying deletions of about half of the DMD gene show very mild symptoms. 11, 12 ese observations suggested a new therapeutic strategy based on the possibility of manipulating the splicing of the dystrophin precursor mRNA in order to induce the skipping of speci c exons and rescuing a correct reading frame. is can be obtained by antisense molecules that, by pairing with splice junctions or exonic splicing enhancers (ESEs), prevent exon recognition by the splicing machinery.
Di erent groups developed chemically modi ed antisense oligo nucleotides (AONs) directed against splice junctions or ESEs, and found that this strategy could e ectively rescue dystrophin both in vitro 13 and in vivo. [14] [15] [16] Safety and local e cacy of the intramuscular AON injections were tested in phase I clinical trials and systemic trials recently started. 17, 18 Small nuclear RNAs (snRNA) have also been utilized as vectors for stable antisense expression in order to circumvent the major limitation of the AON approach that, given the limited oligo stability, requires reiterative administrations. U1 and U7 snRNAderived antisense molecules have been shown to be e ective in inducing exon skipping and dystrophin rescue both in human [19] [20] [21] and in the mdx mouse. [22] [23] [24] Furthermore, long-term and body-wide e ectiveness of the exon-skipping therapy was obtained by systemic injection of adeno-associated viral (AAV) vector expressing the U1-derived antisense molecules into mdx mice. 25 In this article, we tested di erent U1 snRNA-antisense sequences for the ability of inducing exon 51 skipping by targeting di erent combinations of ESEs and splice junctions. Ten di erent antisense molecules were realized and the most e ective construct was selected by a triple screening in DMD myoblasts, in DMD broblasts transdi erentiated into myoblasts and on luciferase reporter construct.
RESULTS
Design and expression analysis of antisense molecules against exon 51 of the DMD gene e U1 snRNA was utilized as carrier to express 10 di erent antisense molecules for exon 51 skipping. Nucleotides from position 3-10 at the 5 -end of U1 snRNA, required for the recognition of the 5 splice site, were substituted with antisense sequences complementary to di erent portions of exon 51 and its splice sites (Figure 1a) . Because we previously observed that both splice sites have to be targeted in order to induce e cient exon skipping, 19 the rst constructs produced contained antisense sequences against both splice junctions (5 3 and 5 3 L constructs; Figure 1b) . Moreover, because ESEs have been shown to represent e ective target substrates for e cient exon skipping 26, 27 we also produced chimeric constructs containing antisense sequences against putative ESE elements, 28 alone or in combination with splice junctions (Figure 1b) . e strong polymerase II-dependent U1 snRNA gene promoter and termination sequences were used to derive antisense expression cassettes, which were cloned in the dU3 portion of the 3 long terminal repeat region of the pRRLSIN.cPPT.PGK/GFP. WPRE lentiviral vector 29 (Figure 2a) . Because the di erent constructs considerably extend the length of the U1 snRNA (in some cases up to 58 nucleotides), we rst checked their expression and stability in HeLa transfection experiments. e relative expression activity was tested by co-transfection with the U16-RBE plasmid 30 and normalized for the endogenous U2 snRNA. Northern blot analysis indicated that all the chimeric molecules accumulated at fairly similar levels (Figure 2b) . Moreover, immuno precipitations of nuclear extracts with U1-70K antibodies followed by reverse transcriptase (RT)-PCR (Figure 2c ) indicated that the U1-chimeric snRNAs are still able to form snRNPs.
31
Study of exon-skipping activity in human DMD myoblasts Lentiviral particles for each of the constructs were produced in 293T cells and used to infect DMD myoblasts (Δ48-50) carrying the deletion of exons 48-50 (provided by the Telethon Neuromuscular Biobank). In this case, skipping of exon 51 allows rescue of the correct reading frame and the production of a dystrophin protein 210 amino acids shorter than the wild type. Δ48-50 cells were infected with comparable amounts of the di erent recombinant lentiviruses. A er infection, they were induced to di erentiate and samples for RNA and protein analysis were collected a er 7 days. constructs, all the samples revealed skipping activity and, among these, 5 3 and 5 3 esx were the most e ective. Notably, the skipping activity paralleled very well the e ciency of dystrophin rescue (Figure 3b) , with constructs 5 3 and 5 3 esx displaying the highest activity.
Comparison between the 5 3 and 5 3 esx constructs was further tested using a luciferase-based splicing-reporter assay 32 in which luciferase is produced only when skipping of the inserted exon 51 is occurring (Figure 3c , upper panel-construct pLucex51). e 5 3 and 5 3 esx expressing plasmids were co-transfected with the pLuc-ex51 and with a Renilla reporter. Luciferase activity assays (Figure 3c , lower panel) indicated that 5 3 esx is inducing a higher level of exon skipping with respect to 5 3 , con rming the data obtained in DMD cells. ese results indicated that the ESE target region present in the 5 3 esx construct plays an important role in exon 51 splicing and that it is able to improve skipping e ciency when combined to antisense sequences against splice junctions.
Exon skipping in DMD fibroblasts transdifferentiated into myoblasts
In order to have a simpli ed screening procedure for testing the activity of antisense constructs on patients' samples, we set up a protocol for broblasts transdi erentiation into myoblasts. Infection of WT broblasts with the MyoD lentivirus (Figure 4a ) produced e cient conversion into myoblasts and myotubes as shown by dystrophin synthesis (Figure 4b ) and morphological analysis (not shown). Dystrophin starts to be produced at 4 days a er shi ing to di erentiation medium and its accumulation increases with the progression of the myogenic program (8 days). We then applied the transdi erentiation protocol to DMD broblasts in order to test the skipping activity of the 5 3 esx construct. A skin biopsy with a di erent genetic background (deletion of exons 45-50 − Δ45-50), also treatable with exon 51 skipping, was infected with the M-U1#51 lentivirus carrying the MyoD and 5 3 esx expression cassettes (Figure 4a) . Muscle di erentiation was induced 2 days a er infection and at day 9 and 13, samples were collected for RNA and protein analysis. Figure 4c shows the expression of MyoD and GFP, which are encoded on the same vector. Figure 4d shows that the expression of the antisense-RNA persisted at 9 and 13 days and it corresponded to a very high e ciency of skipping (almost 50%, Figure 4e ) and rescue of dystrophin synthesis (Figure 4f ).
DISCUSSION
Exon skipping is one of the most promising gene therapy approaches for the treatment of DMD. Two phase I clinical trials have been concluded 17, 18 using di erent kinds of modi ed-AONs delivered to the patients by local intramuscular injections. In both studies, the analysis performed 3-4 weeks a er treatment revealed a high percentage of dystrophin positive bers and proved to be safe and well tolerated.
A parallel strategy to the use of synthetic oligonucleotides is represented by a gene therapy approach in which the antisense molecule is continuously expressed as part of a cellular RNA. Several groups have indeed proven the feasibility of this approach through the use of expression cassettes for snRNAbased antisense molecules delivered to mdx mice muscle cells by AAV vectors. [22] [23] [24] Further studies in the mdx model have also shown that a single systemic injection into young (6 week old) animals of AAV1-U1 antisense-RNA constructs was e ective in maintaining the physiological and molecular bene ts for the entire lifespan of the animals. 25 ese results encouraged the idea that one single treatment could be e ective in providing a longterm bene t and provided the basis for designing protocols with potential applications of AAV-mediated gene therapy in human. e objective of this work was the selection of the most e ective antisense-RNA for the skipping of exon 51 of the human DMD gene. Previous work in our lab indicated that both splice junctions had to be targeted by the antisense molecules in order to produce e cient skipping. 19 However, more recent evidences indicated the very crucial function of ESEs in dictating splicing e ciency 26 and as powerful targets for antisense strategies involving either exon skipping or inclusion. 33 Furthermore ESEs seem to play a critical role in the context of the dystrophin pre-mRNA where the recognition of the correct exon sequences could be hampered by the huge intron size. 34 erefore, in analogy to what has been done for synthetic oligos, it was mandatory to design and test a collection of antisense molecules against di erent combinations of such target sequences in order to select the winner construct for further preclinical and clinical studies. Moreover, due to the utilization of an snRNA carrier, it was important to assess the activity of the di erent antisense combinations when part of the U1 snRNA ribonucleoprotein. Ten di erent U1 snRNA-based constructs combining antisense sequences directed against splice junctions and ESEs were designed, cloned and tested for in vivo stability and exon 51 skipping activity. All of them were shown to stably accumulate in the cell despite the fact that the U1 snRNA size was sometime considerably modi ed by the addition of the antisense sequences. Notably, these molecules were still able to bind the U1-70K protein, which represents an hallmark for the assembly of stable U1 snRNP particles, thus explaining the reason for their stable accumulation in the cell.
e exon 51 skipping behavior of each antisense molecule was tested by infecting myoblasts derived from patient biopsies with the deletion of exons 48-50. is allowed us to select the two best performing molecules (5 3 and 5 3 esx), di ering only for an additional antisense element against a putative ESE in the 5 3 esx construct. Subsequently, their activity was further compared using a luciferase-based splicing-reporter assay that con rmed the higher activity of the 5 3 esx construct. ese data indicated that the ESE target region present in the 5 3 esx construct plays an important role in exon 51 splicing and that, in the U1 snRNA context, is able to improve skipping e ciency when associated to antisense sequences against splice junctions. ese results, together with the fact that the U1 constructs containing only anti-ESE antisense have very poor activities, allowed us to conclude that U1 snRNA works e ciently, as expected, primarily through recognition of splice junctions. is appears to be relevant di erence with the U7 snRNA vector that works e ciently in the recognition of ESE sequences independently from the targeting of splice sites 20, 21 and from synthetic oligos, which act independently of any carrier RNA. 17, 18 e activity of the winner construct was nally tested on a di erent genetic background (deletion 45-50) utilizing transdi erentiated patients' broblasts. e possibility of testing exonskipping activity in broblasts derived from skin biopsies is very important, considering that muscle biopsies are invasive surgical interventions and DMD patients are basically children, already weakened by the course of their pathology.
In conclusion, the results of these studies indicated that the 5 3 esx construct is very active in inducing skipping of exon 51 in two di erent DMD mutant backgrounds and in two di erent cellular systems and therefore, it can be considered the best candidate to be selected for future preclinical and clinical studies.
Previous work in mice indicated that the delivery of AAV viruses carrying U1-antisense expression cassettes provided a very good system for body-wide rescue of dystrophin synthesis. Moreover, the observation that the bene cial e ect of this treatment lasted the entire lifespan of the animal without any secondary/toxic e ect, together with the persistence of expression from AAV vectors in muscle of nonhuman primates for >6 years, 35 suggested that the same strategy could be applied for a long-term treatment of human DMD patients. Translating this approach to large animals or humans is not so obvious due to the high doses of vector required and the immune response to capsid proteins if subsequent injections would be required. However, recent articles demonstrated that the formation of anti-AAV1 antibodies can be successfully abrogated by an immunomodulation treatment, providing a protocol with potential applications to AAV-mediated therapies in humans. 36, 37 Further studies and accurate preclinical tests will be required in order to provide the appropriate answers to these open issues. 
MATERIALS AND METHODS

Antisense clones construction
U1#51 5 3 :
is rst clone was PCR-derived from the previously described U1-5 (ref. 19 ) and double antisense cassette was inserted in the U1 cassette already used for U1#23.
Clones U1#51 were obtained by inverse PCR on the construct pRRL-5 3 .
U1#51 ESE A:
U1#51AON1R (5 -AGAAATGCCATCTTCCTTGAATGAGATCTTGGGCCTCTG C-3 ); U1F2 (5 -GGCAGGGGAGATACCATGATC-3 ). e PCR fragments were digested with NheI and inserted into the NheI-digested pRRLSIN.cPPT.PGK/GFP.WPRE lentiviral backbone. 29 e clone pCCL-MyoD/5 3 esx was derived from pRRL-5 3 ESX with a digestion reaction using endonucleases SalI and ScaI, and cloning the resulting excised insert into the SalI-ScaI-digested pCCL-MyoD ( provided by Maurizia Caruso).
Cell cultures. Cultures of primary myoblasts were rst preplated in order to separate broblasts from the primary line, seeded in Human Skeletal Muscle Growth Medium (PromoCell, Heidelberg, Germany) and grown in a humidi ed incubator, at 5% CO 2 and 37 °C.
Cultures of primary broblasts were established through out-growth from both human DMD and healthy skin biopsies in RPMI with 15% fetal calf serum, 1% penicillin-streptomycin and 1% glutamine (GIBCO/BRL Life Technologies, Grand Island, NY). Fibroblasts were then maintained as described above.
Virus preparation and cell transduction. e 293T cells were plated on 25-cm diameter plates (three plates/virus) and co-transfected with lentiviral constructs and packaging plasmids Plp1, Plp2, and PlpV/SVG (Invitrogen, Carlsbad, CA) according to the four-plasmid transient transfection method previously described. 29 Supernatant was collected for the following 2 days a er the transfection and then centrifuged in a Beckmann Ultracentrifuge at 20,000g for 2 hours. Pellets were resuspended in Hank's balanced salt solution bu er (Invitrogen) .
Transduction e ciency was tested infecting HeLa cells: cells were then collected for RNA and protein extraction, in order to test antisense and GFP expression, respectively. e day before transduction, myoblasts or broblasts were seeded in growth medium, on 60-mm diameter plates (at least two for each di erent virus), at a density of 5 × 10 5 cells per plate. e next 2 days they were infected twice with lentiviruses and polybrene (4 mg/ml). e second day from the last infection, cells were induced to di erentiate with Human Skeletal Muscle Di erentiation Medium (PromoCell). A er 7 days (for myoblasts) or 9 and 13 days (for broblasts) of di erentiation, cells were washed twice with complete phosphate-bu ered saline (PromoCell) and collected with the help of a gum scraper with 300 µl of protein bu er [100 mmol/l Tris-HCl pH 7.4, 1 mmol/l EDTA, 2% sodium dodecyl sulfate, 1× Complete EDTA-free Protease Inhibitor Cocktail (Roche, Applied Science, Mannheim, Germany)] for protein extraction, or with 1 ml of TRIZOL reagent ( Invitrogen) for RNA extraction.
Proteins extraction and analysis. Proteins were extracted from cell plates with 100 mmol/l Tris-HCl (pH 7.4), 1 mmol/l EDTA, 2% sodium dodecyl sulfate (SDS), and a protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany). Samples were placed on a rotary shaker at 4 °C for 30 minutes, centrifuged at 13,200 r.p.m. for 20 minutes at 4 °C and supernatant containing protein extracts was collected. Concentration was assessed with the BCA assay (PIERCE; ermo Fisher Scienti c, Rockford, IL), according to the manufacturer's instructions.
Western blot. Fi y micrograms of protein extracts (for dystrophin and tubulin) were loaded onto a NuPAGE Tris-Acetate Minigel 3-8% 1 mm (Invitrogen); 15 µg (for GFP and MyoD) were run on a NuPAGE Bis-Tris minigel 10% 1 mm (Invitrogen).
RNA preparation and analysis. Cells were harvested with 1 ml of Trizol (Invitrogen) and RNA was extracted according to the manufacturer's instructions; concentration was assessed with Nanodrop ND-1000 Spectrophotometer (CELBIO, Pero, Milan, Italy). A 10 µl of the reactions were run on a 2% agarose-ethidium bromide gel and signals were revealed on a UV transilluminator.
RT-PCR.
Northern blot. Northern analysis was performed as already described. 38 Brie y, 10 µg of total RNA were loaded onto a 6% polyacrylamide gel, run at 17 mA, and transferred into a Hybond-N + nitrocellulose membrane (Amersham, GE Healthcare Life sciences, Buckinghamshire, UK) for 16 hours at 10 volts and 4 °C. Membranes were hybridized with probe -U1 (5 -CAGGGGAAAGCGCGAACGCAGTCCCCCA-3 ) and revealed using a Typhoon TRIO Variable Mode Imager system (Amersham, GE Healthcare Life sciences), with ImageQuant TL.I program.
pLuc-ex51 construction.
e insert ex51 was obtained by PCR from genomic DNA using the oligos:
5 -AAGGAAAAAAGCGGCCGCATGAGAATGAGCAAAATCGT-3 and 5 -CCTTAATTAAGAGACAACTATTCTTGTAAG-3 . e italicized bases are NotI and PacI restriction sites. Ex51 is made of the whole exon 51 anked by 268 bp of intron 50 and 263 bp of intron 51. e PCR fragments were digested with NotI and PacI enzymes and inserted into the NotI and PacI-digested pcDNA3.1-Luc vector. 32 C 2 7 transfections. C2.7 myoblasts 39 are a mouse myogenic cell line derived from the C2 cells, isolated from mouse-activated satellite cells. 40 C 2 7 cells were plated on 35-mm diameter plates; they were co-transfected with 2 g of pLuc-ex51, 2 g of the lentiviral vector carrying the antisense expression cassette and 50 ng of a Renilla Luciferase expressing construct, used as a transfection e ciency control. e transfection was performed according to the Lipofectamine 2000 protocol (Invitrogen). Cells were grown in Dulbecco's modi ed Eagle's medium 10% fetal bovine serum for 36 hours.
Luciferase assay. C 2 7 cells were collected using 250 L of passive lysis buffer and the assay was performed according to Dual-Luciferase Reporter Assay System protocol (Promega).
